Healthcare Industry News:  Cardinal Health 

Biopharmaceuticals Personnel

 News Release - June 27, 2007

SkyePharma PLC - Appointment of New Non-Executive Director

LONDON, UK,--(HSMN NewsFeed)-- Wednesday, June 27, 2007 - SkyePharma PLC (LSE:SKP.L ) today announces that it will appoint a new Non-Executive Director, Jean-Charles Tschudin, with effect from 1 July 2007.

Jean-Charles, 64, is an experienced senior-level pharmaceutical executive with over 40 years' experience in the pharmaceutical industry, most recently with as President and Chief Operating Officer of Yamanouchi Europe, the largest Japanese pharmaceutical company in Europe. Prior to that he held senior positions at Cardinal Health, Johnson & Johnson and Schering-Plough.

Jean-Charles will be appointed as a member of the Audit and Nomination & Governance Committees.

No disclosures are required under section 9.6.13 of the Listing Rules.

The Company is committed to further strengthening its Board and continues to seek to appoint an additional non-executive director.

Dr Jerry Karabelas, Chairman of SkyePharma, said: "On behalf of the whole Board and staff, I would like to welcome Jean-Charles to the Board of SkyePharma. His experience as a senior international manager in the pharmaceutical industry will enable him to make a substantive contribution to the future of SkyePharma."

About SkyePharma PLC

Using its proprietary drug delivery technologies, SkyePharma develops new formulations of known molecules to provide a clinical advantage and life-cycle extension. The Company has eleven approved products in the areas of oral, inhalation and topical delivery. The Group's products are marketed throughout the world by leading pharmaceutical companies.

For more information, visit

Source: SkyePharma

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.